The FDA has started a review of MSD's respiratory syncytial virus (RSV) antibody clesrovimab, with a verdict due in the ...

Russian President Vladimir Putin hinted at this advancement, stating that the country was nearing the completion of its ...

The Russian Health Ministry has announced a groundbreaking development: a cancer vaccine that is set to be launched next year ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on MRK stock, giving a Buy rating on December 11.Pick the best ...

Through its collaboration with Nvidia, Genesis is working to accelerate development of its AI platform, Genesis Exploration ...

Shares of Merck & Co. Inc. MRK were unchanged Tuesday, on what proved to be an all-around dismal trading session for the ...

Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development programs for vibostolimab and ...

Vaccinations provide significant protection for the public against infectious diseases and substantially reduce health care ...

Netflix co-founder Reed Hastings and former New York City mayor Michael Bloomberg made the largest contributions in 2024, and ...

The Russian Ministry of Health claims it will begin distributing vaccinations against cancer as soon as early 2025.

An FDA approval of Merck’s drug clesrovimab by June would give physicians another option for protecting newborns from ...

Merck & Co. on Tuesday said the Food and Drug Administration has accepted its application seeking approval of its proposed clesrovimab vaccine aimed at protecting infants from respiratory syncytial ...